Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

Summary of COVID-19 vaccine AEFI reports received in Saskatchewan

As of June 19, 2022, a cumulative total of 1,297 reports have been received, following 2,508,534 doses of COVID-19 vaccines administered, with a reporting rate of 0.52 per 1,000 doses administered (0.052% of all doses administered). Refer to Tables 1 and 2 for more details.

Table 1: Summary of COVID-19 Vaccine AEFI Reports Received in Saskatchewan, as of June 19, 2022

Pfizer 12+ Moderna AstraZeneca COVISHIELD Janssen Pfizer 5-11 Novavax All combined
Total number of doses administered 1,786,550 518,251 74,923 17,023 1,869 109,610 308 2,508,534
Total number of AEFI reports received 832 312 113 25 3 11 1 1,297
Number of non-serious reports 771 300 95 24 2 10 1 1,203
Number of serious reports1 61 12 18 1 1 1 0 94
Proportion of serious AEFI reports 7% 4% 16% 4% 33% 9% 0% 7%
AEFI reporting rate per 1,000 doses administered 0.47 0.6 1.51 1.47 1.61 0.1 3.4 0.52
Serious AEFI reporting rate per 1,000 doses administered 0.03 0.02 0.24 0.06 0.54 0.01 0 0.04
1Serious criteria includes an adverse event that is life threatening or results in death, requires hospitalization or prolongation of an existing hospitalization, results in residual disability or causes congenital malformation.

Table 2: Cumulative Frequency of AEFIs Reported

Adverse event type # of events
Rashes (all) 245
Anesthesia/paresthesia 216
Edema (allergic, not injection site) 208
Injection site reactions 197
Vomiting/diarrhea/nausea 142
Anaphylaxis 80
Headache 67
Chest tightness 65
Arthralgia/arthritis/joint pain 44
Malaise/lethargy 42
Fever 35

There are safety signals identified by the Public Health Agency of Canada (PHAC) for vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), myocarditis/pericarditis, Guillain-Barre Syndrome (GBS) and capillary leak syndrome (CLS) requiring provinces and territories to report these events as adverse events of special interest to the PHAC. As of June 19, 2022, 3 VITT/TTS, 33 myocarditis/pericarditis, 0 GBS and 0 CLS cases have been reported in Saskatchewan.

Information on reported adverse events following COVID-19 vaccination in Canada can be found at the PHAC AEFI reporting site at COVID-19 vaccine safety: Weekly report on side effects following immunization on

We need your feedback to improve Help us improve